These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 27023695)

  • 1. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
    Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
    J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [No Abstract]   [Full Text] [Related]  

  • 3. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
    Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
    Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.
    Mortimer KM; Bartels DB; Hartmann N; Capapey J; Yang J; Gately R; Enger C
    Respiration; 2020; 99(2):108-118. PubMed ID: 31982886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study).
    Gómez AV; Rodríguez-Nieto MJ; Cano-Jiménez E; Ortiz AR; Morros M; Ramon A; Armengol S
    BMC Pulm Med; 2024 Jul; 24(1):370. PubMed ID: 39080648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 8. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 11. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 12. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.
    Raimundo K; Chang E; Broder MS; Alexander K; Zazzali J; Swigris JJ
    BMC Pulm Med; 2016 Jan; 16():2. PubMed ID: 26732054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
    Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
    J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.
    Yu YF; Macaulay DS; Reichmann WM; Wu EQ; Nathan SD
    Respir Med; 2015 Dec; 109(12):1582-8. PubMed ID: 26607877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization.
    Bengtson LGS; Yu Y; Wang W; Cao F; Hulbert EM; Wolbeck R; Elliott CA; Buikema AR
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1149-1159. PubMed ID: 29083972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
    BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.